This week, Galera’s COO Al Beardsley is attending the 2023 American Society for Radiation Oncology Annual Meeting in San Diego, engaging with fellow innovators in #biotech. #ASTRO23
Galera Therapeutics, Inc.
Pharmaceutical Manufacturing
Malvern, Pennsylvania 9,329 followers
Transforming the science and treatment of cancer
About us
Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
- Website
-
http://www.galeratx.com
External link for Galera Therapeutics, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Malvern, Pennsylvania
- Type
- Public Company
Locations
-
Primary
2 W Liberty Blvd
Malvern, Pennsylvania 19355, US
-
1100 Corporate Square Drive
Suite 264
Creve Coeur, MO 63132, US
Employees at Galera Therapeutics, Inc.
-
Robert Beardsley
CEO/COO - catalysing start-up, scaling, transformation and performance of innovative biopharma companies.
-
Judy Chopack Schnyder
Sr. Vice President, Clinical Operations and Data Management
-
Chris Degnan
Chief Financial Officer at Galera Therapeutics, Inc.
-
Dennis Riley
CSO at Galera Therapeutics
Updates
-
Tomorrow, preclinical data with Galera's superoxide dismutase mimetics in colorectal cancer will be presented in a Poster Q&A Session at the 2023 American Society for Radiation Oncology Annual Meeting by our collaborators at the University of Iowa. Learn more here: https://lnkd.in/gcnp4C5G #ASTRO23
-
-
Today, we celebrate #WorldCancerResearchDay, a day to recognize researchers who are working diligently to find a cure for cancer and develop more effective treatments. One of these treatments is known as #SBRT, a radiation technique offered to cancer patients. Learn more about the potential benefit of SBRT in locally advanced pancreatic cancer below: https://lnkd.in/eRHi5WGH
-
Tomorrow, Galera’s COO Al Beardsley will participate in the panel “Aligning Priorities for the Partnership” at the Longwood Healthcare Leaders Fall Conference in Boston. Learn more here: https://lnkd.in/ejUx_qAb #LongwoodHealthcareLeaders
-
-
Galera’s President and CEO Dr. Mel Sorensen will participate in a fireside chat at H.C. Wainwright & Co., LLC’s 25th Annual Global Investment Conference today. Tune in to the event via live webcast at https://lnkd.in/e92364Sq. #HCWGlobalInvestment2023
-
-
Galera recently announced that our President and CEO Dr. Mel Sorensen will participate in a fireside chat at the H.C. Wainwright & Co., LLC’s 25th Annual Global Investment Conference next week. A live webcast of the event will be available through Galera’s website. #HCWGlobalInvestment2023 More details: https://lnkd.in/eUdsiics
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference | Galera Therapeutics, Inc.
investors.galeratx.com
-
Today, the Company announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding the Company’s New Drug Application for avasopasem manganese for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment. https://lnkd.in/eZxivV-Q
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese | Galera Therapeutics
investors.galeratx.com
-
On this #WorldLungCancerDay, we come together to celebrate the courage of survivors, extend support to patients, and commemorate those we’ve lost. For further insights on World Lung Cancer Day visit the American Lung Association’s website: https://lnkd.in/eu-iEyr
-
-
Today, on World Head and Neck Cancer Day, and every day, Galera honors and commends patients, healthcare providers and caregivers as we raise awareness for #headandneckcancer. #WHNCD2023
-
-
Ahead of World Head and Neck Cancer Day, Galera wants you to be informed about what the risk factors are for #HeadAndNeckCancer.
-